Prognosis in primary effusion lymphoma is associated with the number of body cavities involved

References

• Cesarman E, Chang Y, Moore PS, . Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995;332:1186–1191.
   PubMed Web of Science ®Google Scholar
• Chen YB, Rahemtullah A, Hochberg E. Primary effusion lymphoma. Oncologist 2007;12:569–576.
   PubMed Web of Science ®Google Scholar
• Cesarman E, Nador RG, Aozasa K, . Kaposi's sarcoma-associated herpesvirus in non-AIDS related lymphomas occurring in body cavities. Am J Pathol 1996;149:53–57.
   PubMed Web of Science ®Google Scholar
• Nador RG, Cesarman E, Chadburn A, . Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996;88:645–656.
   PubMed Web of Science ®Google Scholar
• Said J, Cesarman E. Primary effusion lymphoma. In: Swerdlow SH, Campo E, Harris NL, ., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp 260–261.
   Google Scholar
• Boulanger E, Afonso PV, Yahiaoui Y, . Human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin. Am J Transplant 2008;8:707–710.
   PubMed Web of Science ®Google Scholar
• De Filippi R, Iaccarino G, Frigeri F, . Elevation of clonal serum free light chains in patients with HIV-negative primary effusion lymphoma (PEL) and PEL-like lymphoma. Br J Haematol 2009;147: 405–408.
   PubMed Web of Science ®Google Scholar
• Humphrey RW, Davis DA, Newcomb FM, . Human herpesvirus 8 (HHV-8) in the pathogenesis of Kaposi's sarcoma and other diseases. Leuk Lymphoma 1998;28:255–264.
   PubMed Web of Science ®Google Scholar
• Said J. Kaposi's sarcoma-associated herpesvirus (KSHV): a new viral pathogen associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. West J Med 1997;167: 37–38.
   PubMedGoogle Scholar
• Ballestas ME, Chatis PA, Kaye KM. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 1999;284:641–644.
   PubMed Web of Science ®Google Scholar
• Sakakibara S, Ueda K, Nishimura K, . Accumulation of heterochromatin components on the terminal repeat sequence of Kaposi's sarcoma-associated herpesvirus mediated by the latency-associated nuclear antigen. J Virol 2004;78:7299–7310.
   PubMed Web of Science ®Google Scholar
• Friborg J Jr, Kong W, Hottiger MO, . p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 1999;402: 889–894.
   PubMed Web of Science ®Google Scholar
• Radkov SA, Kellam P, Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med 2000;6:1121–1127.
   PubMed Web of Science ®Google Scholar
• Fujimuro M, Wu FY, ApRhys C, . A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nat Med 2003;9:300–306.
   PubMed Web of Science ®Google Scholar
• Rivas C, Thlick AE, Parravicini C, . Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J Virol 2001;75:429–438.
   PubMedGoogle Scholar
• Asou H, Said JW, Yang R, . Mechanisms of growth control of Kaposi's sarcoma-associated herpes virus-associated primary effusion lymphoma cells. Blood 1998;91:2475–2481.
   PubMed Web of Science ®Google Scholar
• Sakakibara S, Tosato G. Viral interleukin-6: role in Kaposi's sarcoma-associated herpesvirus: associated malignancies. J Interferon Cytokine Res 2011;31:791–801.
   PubMed Web of Science ®Google Scholar
• Cesarman E, Mesri EA. Kaposi sarcoma-associated herpesvirus and other viruses in human lymphomagenesis. Curr Top Microbiol Immunol 2007;312:263–287.
   PubMed Web of Science ®Google Scholar
• Dittmer DP, Krown SE. Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus. Curr Opin Oncol 2007;19:452–457.
   PubMed Web of Science ®Google Scholar
• Boulanger E, Gerard L, Gabarre J, . Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 2005;23:4372–4380.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, . Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Kamitsuji Y, Kuroda J, . Comparison of human herpes virus 8 related primary effusion lymphoma with human herpes virus 8 unrelated primary effusion lymphoma-like lymphoma on the basis of HIV: report of 2 cases and review of 212 cases in the literature. Acta Haematol 2007;117:132–144.
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Nomura K, Ueda K, . Human herpesvirus 8-negative malignant effusion lymphoma: a distinct clinical entity and successful treatment with rituximab. Leuk Lymphoma 2005;46:415–419.
   PubMed Web of Science ®Google Scholar
• Perez CL, Rudoy S. Anti-CD20 monoclonal antibody treatment of human herpesvirus 8-associated, body cavity-based lymphoma with an unusual phenotype in a human immunodeficiency virus-negative patient. Clin Diagn Lab Immunol 2001;8:993–996.
   PubMedGoogle Scholar
• Siddiqi T, Joyce RM. A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab. Clin Lymphoma Myeloma 2008;8:300–304.
   PubMedGoogle Scholar
• Bhatt S, Ashlock B, Natkunam Y, . Preclinical activity of brentuximab vedotin (SGN-35) in primary effusion lymphoma (PEL). Blood 2011;118(Suppl. 1): Abstract 3728.
   Google Scholar
• Sarosiek KA, Cavallin LE, Bhatt S, . Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma. Proc Natl Acad Sci USA 2010;107:13069–13074.
   PubMed Web of Science ®Google Scholar
• Matta H, Chaudhary PM. The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells. Cancer Biol Ther 2005;4:77–82.
   PubMed Web of Science ®Google Scholar
• An J, Sun Y, Fisher M, . Antitumor effects of borte-zomib (PS-341) on primary effusion lymphomas. Leukemia 2004;18: 1699–1704.
   PubMed Web of Science ®Google Scholar
• Waddington TW, Aboulafia DM. Failure to eradicate AIDS-associated primary effusion lymphoma with high-dose chemotherapy and autologous stem cell reinfusion: case report and literature review. AIDS Patient Care STDS 2004;18:67–73.
   PubMed Web of Science ®Google Scholar
• Won JH, Han SH, Bae SB, . Successful eradication of relapsed primary effusion lymphoma with high-dose chemotherapy and autologous stem cell transplantation in a patient seronegative for human immunodeficiency virus. Int J Hematol 2006;83:328–330.
   PubMed Web of Science ®Google Scholar